glp-1 receptor expression papillary thyroid carcinoma Glucagon-like peptide 1 agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research Frontiers | Drug repositioning in

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Prescription GLP-1 medications (Tirzepatide) Patients struggling with weight loss despite diet and exercise Mimics natural gut hormones to regulate appetite and blood sugar Gradual, sustainable weight loss with lifestyle support Medical weight loss refers to a physician-supervised program that uses prescription medications, lifestyle guidance, and ongoing monitoring to help individuals lose weight and improve their health

With the US GLP-1 market valued at $49.3bn in 2024, and growing at a CAGR of 11%1, there is tremendous demand as these therapies become the go-to options for weight loss

it doesn't limit them